Literature DB >> 12413932

Clinical management potential tumours of low malignancy.

David M Gershenson1.   

Abstract

Approximately 3000 American women are diagnosed with borderline ovarian tumours annually. Common signs and symptoms include abdominal/pelvic pain and a palpable adnexal mass. Pelvic sonography may be helpful, although not specific, in the diagnosis. Serum CA 125 is abnormal in only about 50% of patients. Primary surgery is the principal treatment; it consists of resection of the primary tumour(s) (frequently in the form of fertility-sparing surgery), frozen-section analysis and consideration of comprehensive surgical staging. The role of surgical staging remains unclear; further research is necessary. For patients with stage I disease, surgery alone is the standard. For patients with stage II-IV disease (with non-invasive or invasive peritoneal implants), the role of post-operative therapy remains unclear. Approximately 20-30% of the latter will relapse, frequently after several years. Most so-called recurrences are low-grade carcinomas. Potential predictive or prognostic factors include age, FIGO stage, residual disease and the micropapillary pattern. After fertility-sparing surgery, most patients retain normal reproductive function.

Entities:  

Mesh:

Year:  2002        PMID: 12413932     DOI: 10.1053/beog.2002.0308

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  11 in total

1.  Management of Borderline Ovarian Tumors-Still a Gray Zone.

Authors:  Nidhi Nayyar; Prerna Lakhwani; Ashish Goel; Pankaj Kr Pande; Kapil Kumar
Journal:  Indian J Surg Oncol       Date:  2017-08-25

2.  Risk factors for recurrence of ovarian borderline tumors.

Authors:  K K Shih; Q Zhou; J Huh; J C Morgan; A Iasonos; C Aghajanian; D S Chi; R R Barakat; N R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2010-12-10       Impact factor: 5.482

3.  Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.

Authors:  Helen J Mackay; Hal Hirte; Terrence Colgan; Al Covens; Katrina MacAlpine; Pamela Grenci; Lisa Wang; Jaqueline Mason; Pnu-An Pham; Ming-S Tsao; James Pan; James Zwiebel; Amit M Oza
Journal:  Eur J Cancer       Date:  2010-03-19       Impact factor: 9.162

Review 4.  Borderline tumours of the ovary, current controversies regarding their diagnosis and treatment.

Authors:  María Guadalupe Patrono; Lucas Minig; Ivan Diaz-Padilla; Nuria Romero; Juan Francisco Rodriguez Moreno; Jesus Garcia-Donas
Journal:  Ecancermedicalscience       Date:  2013-12-17

Review 5.  Fertility sparing treatment in borderline ovarian tumours.

Authors:  Rosa Maria Alvarez; Daniel Vazquez-Vicente
Journal:  Ecancermedicalscience       Date:  2015-02-03

6.  Hereditary risk evaluation for borderline ovarian tumors based on immunohistochemistry.

Authors:  Jung Min Park; Min Kyu Kim
Journal:  J Menopausal Med       Date:  2014-04-28

7.  Short-term Outcomes and Pregnancy Rate After Laparoscopic Fertility-Sparing Surgery for Borderline Ovarian Tumors: A Single-Institute Experience.

Authors:  Jianguo Zhao; Caiyan Liu; Jing Liu; Pengpeng Qu
Journal:  Int J Gynecol Cancer       Date:  2018-02       Impact factor: 3.437

Review 8.  Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria.

Authors:  Steffen Hauptmann; Katrin Friedrich; Raymond Redline; Stefanie Avril
Journal:  Virchows Arch       Date:  2016-12-27       Impact factor: 4.064

Review 9.  Serous borderline ovarian tumours: an extensive review on MR imaging features.

Authors:  Hilal Sahin; Asli Irmak Akdogan; Janette Smith; Jeries Paolo Zawaideh; Helen Addley
Journal:  Br J Radiol       Date:  2021-07-08       Impact factor: 3.629

10.  Borderline ovarian tumors: clinical characteristics, management, and outcomes - a multicenter study.

Authors:  Mehmet Gokcu; Kemal Gungorduk; Osman Aşıcıoğlu; Nilüfer Çetinkaya; Tayfun Güngör; Gonca Pakay; Zeliha Fırat Cüylan; Tayfun Toptaş; Ramazan Özyurt; Elif Ağaçayak; Aykut Ozdemir; Onur Erol; Anıl Turan; Varol Gülseren; Mehmet Sait İcen; Taylan Şenol; Hakan Güraslan; Burcu Yücesoy; Ahmet Sahbaz; Ozgu Gungorduk; Berhan Besimoğlu; Kaan Pakay; Osman Temizkan; Muzaffer Sancı; Tayup Şimşek; Mehmet Mutlu Meydanlı; Mehmet Harma; Levent Yaşar; Birtan Boran; Aysel Derbent Uysal; Ateş Karateke
Journal:  J Ovarian Res       Date:  2016-10-18       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.